ACHP nnel blocker-1 3)57-41(51)50-18-17-49(27-32(50)12-14-43)39-36-13-16-48(38-11-7-9-31-8-5-6-10-35(31)38)29-37(36)45-40(46-39)56-30-33-26-34(28-47(33)4)55-25-24-54-23-22-53-21-20-52-19-15-44/h5-11

3)57-41(51)50-18-17-49(27-32(50)12-14-43)39-36-13-16-48(38-11-7-9-31-8-5-6-10-35(31)38)29-37(36)45-40(46-39)56-30-33-26-34(28-47(33)4)55-25-24-54-23-22-53-21-20-52-19-15-44/h5-11

L-Palmitoylcarnitine (1 µM) inhibits KATP channel activity

InChi: InChI=1S/C17H16O9/c18-6-11-13(20)14(21)15(22)17(25-11)26-16-7-1-2-12(19)24-10(7)5-9-8(16)3-4-23-9/h1-5

Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA)

Smiles: CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C=O

ACHP nnel blocker-1 3)57-41(51)50-18-17-49(27-32(50)12-14-43)39-36-13-16-48(38-11-7-9-31-8-5-6-10-35(31)38)29-37(36)45-40(46-39)56-30-33-26-34(28-47(33)4)55-25-24-54-23-22-53-21-20-52-19-15-44/h5-11IC50: 8. 5 and 250 nM for IKK and IKK, respectively ACHP is an IB kinase inhibitor. Nuclear factor KB (NF KB) involved in cell survival and proliferation of multiple myeloma has been well established. In vitro: ACHP is selective for IKK and IKK over IKK3, Syk and MAPKKK4 (IC50 > 20 M), DNA binding activity of NF B is inhibited. ACHP is an effective blockade NF B pathway in multiple myeloma cell lines, and induces cell growth arrest and apoptosis. It